Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial
Circulation · 30.05.2023 · 147 (22) · 1654-1669
DOI: 10.1161/circulationaha.122.062021 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 30.05.2023. Verfasst von Moritz J Hundertmark und 20 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Centre for Clinical Magnetic Resonance Research (M.J.H., H.L., S.M., F.E.M., B.R., O.R., C.T.R., L.V., M.M., S.N.), Division of Cardiovascular…. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, British Heart Foundation.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness.
Methods
EMPA-VISION (Assessment of Cardiac Energy Metabolism, Function and Physiology in Patients With Heart Failure Taking Empagliflozin) is a prospective, randomized, double-blind, placebo-controlled, mechanistic trial that enrolled 72 symptomatic patients with chronic HF with reduced ejection fraction (HFrEF; n=36; left ventricular ejection fraction ≤40%; New York Heart Association class ≥II; NT-proBNP [N-terminal pro-B-type natriuretic peptide] ≥125 pg/mL) and HF with preserved ejection fraction (HFpEF; n=36; left ventricular ejection fraction ≥50%; New York Heart Association class ≥II; NT-proBNP ≥125 pg/mL). Patients were stratified into respective cohorts (HFrEF versus HFpEF) and randomly assigned to empagliflozin (10 mg; n=35: 17 HFrEF and 18 HFpEF) or placebo (n=37: 19 HFrEF and 18 HFpEF) once daily for 12 weeks. The primary end point was a change in the cardiac phosphocreatine:ATP ratio (PCr/ATP) from baseline to week 12, determined by phosphorus magnetic resonance spectroscopy at rest and during peak dobutamine stress (65% of age-maximum heart rate). Mass spectrometry on a targeted set of 19 metabolites was performed at baseline and after treatment. Other exploratory end points were investigated.
Results
Empagliflozin treatment did not change cardiac energetics (ie, PCr/ATP) at rest in HFrEF (adjusted mean treatment difference [empagliflozin – placebo], –0.25 [95% CI, –0.58 to 0.09]; P =0.14) or HFpEF (adjusted mean treatment difference, –0.16 [95% CI, –0.60 to 0.29]; P =0.47]. Likewise, there were no changes in PCr/ATP during dobutamine stress in HFrEF (adjusted mean treatment difference, –0.13 [95% CI, –0.35 to 0.09]; P =0.23) or HFpEF (adjusted mean treatment difference, –0.22 [95% CI, –0.66 to 0.23]; P =0.32). No changes in serum metabolomics or levels of circulating ketone bodies were observed.
Conclusions
In patients with either HFrEF or HFpEF, treatment with 10 mg of empagliflozin once daily for 12 weeks did not improve cardiac energetics or change circulating serum metabolites associated with energy metabolism when compared with placebo. Based on our results, it is unlikely that enhancing cardiac energy metabolism mediates the beneficial effects of SGLT2i in HF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03332212.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oxford Centre for Clinical Magnetic Resonance Research (M.J.H., H.L., S.M., F.E.M., B.R., O.R., C.T.R., L.V., M.M., S.N.), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Joh…
- Department of Internal Medicine I, University Hospital Wuerzburg, Germany (M.J.H.).
- Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine (A.A., R.C., R.R.H., J.E.M.), University of Oxford, UK.
- Acute Multidisciplinary Imaging and Interventional Centre (C.A., S.N.), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, UK.
- Boehringer Ingelheim International GmbH, Ingelheim, Germany (J.L.).
- John Radcliffe Hospital, Oxford University Hospitals National Health Service Foundation Trust, UK (J.L., E.W.).
ORCID-Profile: Moritz J Hundertmark, Amanda Adler, Charalambos Antoniades, Ruth Coleman, Julian L Griffin, Rury R Holman, Jack J J J Miller, Shveta Monga, Areesha Nazeer, Betty Raman, Oliver Rider, Christopher T Rodgers, Ladislav Valkovič, Stefan Neubauer
Förderung
- Wellcome Trust
- British Heart Foundation
Zitieren
APA
Hundertmark, M. J., Adler, A., Antoniades, C., Coleman, R., Griffin, J. L., Holman, R. R., Lamlum, H., Lee, J., Massey, D., Miller, J. J. J. J., Milton, J. E., Monga, S., Mózes, F. E., Nazeer, A., Raman, B., Rider, O., Rodgers, C. T., Valkovič, L., Wicks, E., …, & Neubauer, S. (2023). Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial. Circulation, 147(22), 1654-1669. https://doi.org/10.1161/circulationaha.122.062021
Vancouver
Hundertmark MJ, Adler A, Antoniades C, Coleman R, Griffin JL, Holman RR, et al. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial. Circulation. 2023;147(22):1654-1669. doi:10.1161/circulationaha.122.062021
BibTeX
@article{Hundertmark2023,
author = {Hundertmark, Moritz J and Adler, Amanda and Antoniades, Charalambos and Coleman, Ruth and Griffin, Julian L and Holman, Rury R and Lamlum, Hanan and Lee, Jisoo and Massey, Daniel and Miller, Jack J J J and Milton, Joanne E and Monga, Shveta and Mózes, Ferenc E and Nazeer, Areesha and Raman, Betty and Rider, Oliver and Rodgers, Christopher T and Valkovič, Ladislav and Wicks, Eleanor and Mahmod, Masliza and Neubauer, Stefan},
title = {Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial},
journal = {Circulation},
year = {2023},
volume = {147},
number = {22},
pages = {1654--1669},
doi = {10.1161/circulationaha.122.062021}
}
EUVIMED